ArticleDiscover oncology2026
Integrated multi-omics analysis of neutrophil extracellular trap-related genes in renal cell carcinoma using bioinformatics and machine learning.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundRenal cell carcinoma (RCC) poses high recurrence/metastasis risk with limited advanced therapy. The role of neutrophil extracellular traps (NETs) in RCC remains unclear. This study aims to identify core NET-related genes and validate their molecular subtyping and prognostic value.
methodsFive GEO datasets were integrated to identify DEGs, subsequent functional enrichment and WGCNA extracted key modules that were cross-referenced with potential genes systematically compiled from GeneCards and literature review. Three machine learning algorithms (LASSO, SVM-RFE, RF) were refined core genes. ROC analysis validated diagnostic performance, and a nomogram was constructed. Consensus clustering defined molecular subtypes, which were subsequently characterized by immune infiltration, pathway activity, and validated in the independent TCGA-KIRC cohort for prognosis and clinicopathological correlations.
resultsWe identified eight core NET-related genes with excellent diagnostic accuracy (AUCs 0.989/0.987). Based on these genes, patients were classified into two molecular subtypes: the C1 subtype exhibited high immune cell infiltration, particularly of activated CD8⁺ T cells and MDSCs, but was associated with poor prognosis and advanced tumor stage, while the C2 subtype showed low immune infiltration, was enriched in metabolic pathways, and correlated with favorable survival outcomes. Drug sensitivity analysis identified Capsaicin as a potential therapeutic agent.
conclusionThe eight-gene NET signature demonstrates strong diagnostic accuracy and enables molecular subtyping of RCC with validated prognostic significance, highlighting its potential as a prognostic biomarker and therapeutic guide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.